Understand the source comparison
Peptide Protocols for Osteoporosis: Research Dosing Comparison
Before selecting a peptide and dose for bone density research, compare the mechanisms, typical dosing ranges, administration frequency, and timeline to measurable outcomes. This table shows the primary peptides used in osteoporosis studies and how they differ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide and dose for bone density research, compare the mechanisms, typical dosing ranges, administration frequency, and timeline to measurable outcomes. This table shows the primary peptides used in osteoporosis studies and how they differ in application.
- MK-677 (Ibutamoren)
- GH secretagogue. Increases IGF-1 and stimulates osteoblast activity
- 10–25mg daily
- Once daily (evening preferred)
- Detectable increase in bone formation markers (P1NP) at 8–12 weeks; DEXA-measurable density change at 6–9 months
- Best for anabolic bone formation research; requires long study duration but produces sustained density gains
- Thymalin
- Thymic peptide. Modulates immune-driven bone resorption via cytokine suppression
- 10mg per injection
- 2–3 times per week
- Reduction in inflammatory markers (IL-6, TNF-alpha) within 4–6 weeks; bone turnover markers stabilize at 12–16 weeks
- Ideal for autoimmune or inflammatory bone loss models; complements anabolic agents
- CJC-1295 + Ipamorelin
- GHRH analog + ghrelin mimetic. Pulsatile GH release without cortisol elevation
- 100–300mcg each per injection
- 3–5 times per week
- Serum IGF-1 elevation within 2 weeks; bone formation markers increase at 6–8 weeks
- Shorter half-life than MK-677; requires more frequent dosing but allows precise control of GH peaks
- BPC-157
- Tissue repair peptide. Promotes angiogenesis and collagen synthesis in bone microenvironment
- 250–500mcg per injection
- Once or twice daily
- Accelerated fracture healing observed in animal models at 4–6 weeks; human DEXA data limited
- Primarily used in fracture repair studies rather than osteoporosis prevention; strong mechanistic rationale but less clinical data